AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced financial results for its fiscal 2010 second quarter ended September 30, 2009.
Total revenues for the three months ended September 30, 2009 were $518,000 as compared with $989,000 for the comparable prior year period, a decrease of $471,000, or 47.6%. Total revenues for the six months ended September 30, 2009 were $968,000 as compared with $1,863,000 for the comparable prior year period, a decrease of $895,000, or 48.0%.
Product sales of our biomaterials for the three months ended September 30, 2009 were $316,000 as compared with $409,000 for the comparable prior year period, a decrease of $93,000, or 22.7%. Product sales of our biomaterials for the six months ended September 30, 2009 were $555,000 as compared with $722,000 for the comparable prior year period, a decrease of $167,000, or 23.1%. Although the three and six month period product sales decreased as compared with the comparable prior year periods, primarily due to a decrease in shipments of our biomaterials to our existing customer base, in the second quarter of fiscal 2010 the Company realized a $77,000, or 32.2%, increase in product sales over the first quarter of fiscal 2010. The sequential quarter growth is attributable to product sales to new customers in addition to increased sales to our existing customer base.
License, royalty and development fees for the three months ended September 30, 2009 were $202,000 as compared with $580,000 for the comparable prior year period, a decrease of $378,000 or 65.2%. License, royalty and development fees for the six months ended September 30, 2009 were $413,000 as compared with $1,141,000 for the comparable prior year period, a decrease of $728,000 or 63.8%. The decrease in license, royalty and development fees during the three and six month periods ended September 30, 2009 is primarily a result of an amendment to an agreement with a major customer from whom we derive a majority of our license, royalty and development fee revenue. The amendment to this agreement resulted in the reduction of royalty fees paid to us per unit of sale of our customer’s product.
Gross profit on total revenues for the three months ended September 30, 2009 was $227,000, or 43.8% of total revenues, compared with $609,000, or 61.6% of total revenues, for the comparable prior year period. Gross profit on total revenues for the six months ended September 30, 2009 was $338,000, or 34.9% of total revenues, compared with $1,136,000, or 61.0% of total revenues, for the comparable prior year period. The decrease in gross profit dollars and gross profit as a percentage of total revenues is due to the decrease of product sales and license, royalty and development fees compared to the prior year period.
Gross profit on product sales for the three months ended September 30, 2009 was $25,000, or 7.9% of product sales, compared with gross profit of $29,000, or 7.1% of product sales, for the comparable prior year period. Gross profit on product sales for the six months ended September 30, 2009 was a loss of $75,000, or 13.5% of product sales, compared with a loss of $5,000, or 0.7% of product sales, for the comparable prior year period. Gross profit on product sales was much improved for the second quarter of fiscal 2010 as compared with the first quarter of fiscal 2010, where we reported a loss of $100,000 or 41.8%. The improved gross margin in the second quarter of fiscal 2010 is a result of increased product sales within a relatively stable fixed cost environment and continued improvements in operating efficiencies.
Research and development expenses for the three months ended September 30, 2009 were $159,000 as compared with $231,000 for the comparable prior year period, a decrease of $72,000 or 31.2%. Research and development expenses for the six months ended September 30, 2009 were $341,000 as compared with $414,000 for the comparable prior year period, a decrease of $73,000 or 17.6%. During the three and six month periods ended September 30, 2009, we increased our research and development expenditures in the development of new biomaterials and related applications while expenditures related to the CardioPass clinical trials decreased.
Selling, general and administrative expenses for the three months ended September 30, 2009 were $610,000 as compared with $722,000 for the comparable prior year period, a decrease of $112,000 or 15.5%. Selling, general and administrative expenses for the six months ended September 30, 2009 were $1,396,000 as compared with $1,646,000 for the comparable prior year period, a decrease of $250,000 or 15.2%. The decrease is primarily attributable to our cost containment measures which included reductions in outside consultants and insurance costs.
During the three months ended September 30, 2009, we realized approximately $729,000 of additional gain on the sale of Gish Biomedical Inc. (“Gish”), our former subsidiary, upon the settlement of our dispute with Medos. During the six months ended September 30, 2009, we realized approximately $942,000 of additional gains on the sales of our former Catheter and Disposables Technology, Inc. (“CDT”) and Gish subsidiaries.
As of September 30, 2009, we had cash and cash equivalents of $3,628,000 as compared to $3,873,000 as of March 31, 2009.
Michael F. Adams, President and CEO of AdvanSource, stated, “We are pleased with the continued progress being made in sequential quarterly biomaterial product sales growth, and improving margins resulting from our continued efforts to improve production efficiencies. In addition, a key driver of our business model is the acquisition of new customers who will utilize our biomaterials as an integral component of their medical devices. The recent announcements of multi-year development agreements demonstrate our commitment to acquiring customers so as to provide our custom polymer synthesis capabilities to leading innovators in the medical device marketplace.”
Mr. Adams added, “The receipt of funds from the escrow established in connection with the sale of CDT and settlement of the MEDOS dispute should provide added strength to our financial position in the near-term. Of equal importance is the elimination of a potentially costly distraction with the settlement of the Medos dispute. While being cognizant of containing our costs, we expect to invest in our sales and marketing efforts to drive sales, and in our research and development efforts to drive product innovation. We look forward to discussing the Company’s financial and operating performance and future prospects in a conference call to be scheduled at a later date.”
Diet's role in fighting vitiligo highlighted in new research